PF-610355
{{Drugbox | Watchedfields = changed | verifiedrevid = | IUPAC_name = N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2- {[(2R)-2-hydroxy-2- {4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide | image =…
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
{{Drugbox | Watchedfields = changed | verifiedrevid = | IUPAC_name = N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2- {[(2R)-2-hydroxy-2- {4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide | image = PF-610355.svg | image_class = skin-invert-image | width = 230 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | routes_of_administration = Inhalation | legal_status = Development terminated | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 862541-45-5 | ATC_prefix = None | ATC_suffix = | PubChem = 11505444 | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 9680243 | UNII_Ref = | UNII = ZH5SMU97AJ | ChEMBL_Ref = | ChEMBL = 1240967 | C = 34 | H = 39 | N = 3 | O = 6 | S = 1 | smiles = | StdInChI = | StdInChIKey = }} PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable ultra-long-acting β 2 adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state.…
{{Drugbox | Watchedfields = changed | verifiedrevid = | IUPAC_name = N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2- {[(2R)-2-hydroxy-2- {4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide | image = PF-610355.svg | image_class = skin-invert-image | width = 230 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | routes_of_administration = Inhalation | legal_status = Development terminated | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 862541-45-5 | ATC_prefix = None | ATC_suffix = | PubChem = 11505444 | IUPHAR_ligand = | DrugBank_Ref = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 9680243 | UNII_Ref = | UNII = ZH5SMU97AJ | ChEMBL_Ref = | ChEMBL = 1240967 | C = 34 | H = 39 | N = 3 | O = 6 | S = 1 | smiles = | StdInChI = | StdInChIKey = }} PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable ultra-long-acting β 2 adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state.
Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically mediated adverse events. Its in vivo duration on action confirmed its potential for once-daily use in humans. The investigation and development of PF-610355 were discontinued in 2011, likely for strategic and regulatory reasons.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1337212706 under CC BY-SA 4.0; modifications have been made.